Edesa Biotech Statistics
Total Valuation
Edesa Biotech has a market cap or net worth of $28.91 million. The enterprise value is $18.58 million.
| Market Cap | 28.91M |
| Enterprise Value | 18.58M |
Important Dates
The next estimated earnings date is Friday, December 11, 2026, after market close.
| Earnings Date | Dec 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Edesa Biotech has 13.51 million shares outstanding. The number of shares has increased by 72.33% in one year.
| Current Share Class | 13.51M |
| Shares Outstanding | 13.51M |
| Shares Change (YoY) | +72.33% |
| Shares Change (QoQ) | +5.46% |
| Owned by Insiders (%) | 10.62% |
| Owned by Institutions (%) | 23.05% |
| Float | 8.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 51.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.76, with zero debt.
| Current Ratio | 2.76 |
| Quick Ratio | 2.70 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -122.93% and return on invested capital (ROIC) is -79.70%.
| Return on Equity (ROE) | -122.93% |
| Return on Assets (ROA) | -66.43% |
| Return on Invested Capital (ROIC) | -79.70% |
| Return on Capital Employed (ROCE) | -166.02% |
| Weighted Average Cost of Capital (WACC) | 11.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$829,528 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Edesa Biotech has paid $800 in taxes.
| Income Tax | 800 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.59% in the last 52 weeks. The beta is 1.24, so Edesa Biotech's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | +29.59% |
| 50-Day Moving Average | 3.54 |
| 200-Day Moving Average | 5.68 |
| Relative Strength Index (RSI) | 26.08 |
| Average Volume (20 Days) | 47,287 |
Short Selling Information
The latest short interest is 161,309, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 161,309 |
| Short Previous Month | 203,556 |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 3.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.63M |
| Pretax Income | -14.10M |
| Net Income | -14.10M |
| EBITDA | -14.53M |
| EBIT | -14.63M |
| Earnings Per Share (EPS) | -$1.73 |
Balance Sheet
The company has $10.33 million in cash and no debt, with a net cash position of $10.33 million or $0.76 per share.
| Cash & Cash Equivalents | 10.33M |
| Total Debt | n/a |
| Net Cash | 10.33M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 8.81M |
| Book Value Per Share | 0.04 |
| Working Capital | 6.87M |
Cash Flow
| Operating Cash Flow | -8.91M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 102,844 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.91M |
| FCF Per Share | -$0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Edesa Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -72.33% |
| Shareholder Yield | -72.33% |
| Earnings Yield | -80.93% |
| FCF Yield | -30.38% |
Analyst Forecast
The average price target for Edesa Biotech is $16.33, which is 663.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.33 |
| Price Target Difference | 663.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 11, 2023. It was a reverse split with a ratio of 1:7.
| Last Split Date | Oct 11, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |